![]() |
|
|
Vol. 29, Issue 9, 1196-1200, September 2001
Merck Frosst Canada, Kirkland, Québec, Canada
(N.C., B.D., R.L.L., K.B., D.A.N.-G.); and GENTEST Corporation, BD
Biosciences, Woburn, Massachussets (D.M.S., J.M.A., S.D.T., V.P.M.,
C.L.C.)
Recently, a novel nonfluorescent probe
3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin
(AMMC), which produces a fluorescent metabolite AMHC
(3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-hydroxy-4-methylcoumarin) was used with microsomes containing recombinant enzymes (rCYP) to
monitor CYP2D6 inhibition in a microtiter plate assay. This article
describes the studies that were performed in human liver microsomes
(HLM) to establish the selectivity of AMMC toward CYP2D6. Metabolism
studies in HLM showed that AMMC was converted to one metabolite
identified by mass spectrometry as AMHC. Kinetic studies indicated an
apparent Km of 3 µM with a
Vmax of 20 pmol/min · mg of protein
for the O-demethylation reaction. The
O-demethylation of AMMC in HLM was inhibited
significantly in the presence of a CYP2D6 inhibitory antibody. Using a
panel of various HLM preparations (n = 12), a good
correlation (r2 = 0.95) was obtained
between AMMC O-demethylation and bufuralol metabolism, a
known CYP2D6 substrate, but not with probes for the other major
xenobiotic metabolizing CYPs. Finally, only rCYP2D6 showed detectable
metabolism in experiments conducted with rCYPs using AMMC at a
concentration of 1.5 µM (near Km).
However, at a concentration of 25 µM AMMC, rCYP1A also contributed
significantly to the formation of AMHC. Knowing the experimental
conditions under which AMMC was selective for CYP2D6, a microtiter
assay was developed to study the inhibition of various compounds in HLM
using the fluorescence of AMHC as an indication of CYP2D6 activity. The
inhibition potential of various chemicals was found to be comparable to
those determined using the standard CYP2D6 probe, bufuralol, which
requires high-performance liquid chromatography separation for the
analysis of its CYP2D6-mediated 1'-hydoxylated metabolite.
This article has been cited by other articles:
![]() |
S. Sudsakorn, J. Skell, D. A. Williams, T. J. O'Shea, and H. Liu Evaluation of 3-O-Methylfluorescein as a Selective Fluorometric Substrate for CYP2C19 in Human Liver Microsomes Drug Metab. Dispos., June 1, 2007; 35(6): 841 - 847. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Donato, N. Jimenez, J. V. Castell, and M. J. Gomez-Lechon FLUORESCENCE-BASED ASSAYS FOR SCREENING NINE CYTOCHROME P450 (P450) ACTIVITIES IN INTACT CELLS EXPRESSING INDIVIDUAL HUMAN P450 ENZYMES Drug Metab. Dispos., July 1, 2004; 32(7): 699 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Stresser, S. D. Turner, A. P. Blanchard, V. P. Miller, and C. L. Crespi Cytochrome P450 Fluorometric Substrates: Identification of Isoform-Selective Probes for Rat CYP2D2 and Human CYP3A4. Drug Metab. Dispos., July 1, 2002; 30(7): 845 - 852. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Marcucci, R. E. Pearce, C. Crespi, D. T. Steimel, J. S. Leeder, and A. Gaedigk Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine Drug Metab. Dispos., May 1, 2002; 30(5): 595 - 601. [Abstract] [Full Text] [PDF] |
||||